BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34405395)

  • 1. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
    Br J Haematol; 2021 Nov; 195(4):571-584. PubMed ID: 34405395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of adult T-cell leukemia-lymphoma].
    Fukushima T
    Rinsho Ketsueki; 2014 Oct; 55(10):1952-61. PubMed ID: 25297760
    [No Abstract]   [Full Text] [Related]  

  • 3. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
    Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
    Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.
    Imaizumi Y; Iwanaga M; Nosaka K; Ishitsuka K; Ishizawa K; Ito S; Amano M; Ishida T; Uike N; Utsunomiya A; Ohshima K; Tanaka J; Tokura Y; Tobinai K; Watanabe T; Uchimaru K; Tsukasaki K;
    Cancer Sci; 2020 Dec; 111(12):4567-4580. PubMed ID: 32976684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
    Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
    Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia.
    Ureshino H; Miyahara M
    Ann Hematol; 2016 Apr; 95(5):841-3. PubMed ID: 26923458
    [No Abstract]   [Full Text] [Related]  

  • 7. [Progress of the ATLL study: an overview].
    Yamada Y
    Rinsho Ketsueki; 2005 May; 46(5):339-49. PubMed ID: 16444967
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.
    Yamada Y; Tomonaga M; Fukuda H; Hanada S; Utsunomiya A; Tara M; Sano M; Ikeda S; Takatsuki K; Kozuru M; Araki K; Kawano F; Niimi M; Tobinai K; Hotta T; Shimoyama M
    Br J Haematol; 2001 May; 113(2):375-82. PubMed ID: 11380402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
    Toriyama E; Imaizumi Y; Taniguchi H; Taguchi J; Nakashima J; Itonaga H; Sato S; Ando K; Sawayama Y; Hata T; Fukushima T; Miyazaki Y
    Int J Hematol; 2018 Aug; 108(2):167-175. PubMed ID: 29651666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
    Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
    J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adult T-cell leukemia/lymphoma of bone with multiple pathological fractures].
    Yamamoto Y; Ishii K; Nomura S; Fukuhara S
    Rinsho Ketsueki; 2004 Mar; 45(3):247-9. PubMed ID: 15103941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
    Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
    J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
    Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
    Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat adult T-cell leukemia/lymphoma.
    Cook LB; Phillips AA
    Blood; 2021 Jan; 137(4):459-470. PubMed ID: 33075812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Sakamoto Y; Ishida T; Masaki A; Takeshita M; Iwasaki H; Yonekura K; Tashiro Y; Ito A; Kusumoto S; Utsunomiya A; Iida S; Ueda R; Inagaki H
    Br J Haematol; 2021 Jan; 192(2):281-291. PubMed ID: 33205842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum tryptophan catabolism as an indicator of disease activity in adult T-cell leukemia/lymphoma.
    Hoshi M; Ito H; Fujigaki H; Takemura M; Takahashi T; Tomita E; Ohyama M; Tanaka R; Ohtaki H; Saito K; Seishima M
    Leuk Lymphoma; 2009 Aug; 50(8):1372-4. PubMed ID: 19544139
    [No Abstract]   [Full Text] [Related]  

  • 18. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support.
    Taguchi H; Kinoshita KI; Takatsuki K; Tomonaga M; Araki K; Arima N; Ikeda S; Uozumi K; Kohno H; Kawano F; Kikuchi H; Takahashi H; Tamura K; Chiyoda S; Tsuda H; Nishimura H; Hosokawa T; Matsuzaki H; Momita S; Yamada O; Miyoshi I
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):182-6. PubMed ID: 8680890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Sakamoto Y; Ishida T; Masaki A; Murase T; Ohtsuka E; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
    Hematol Oncol; 2022 Dec; 40(5):876-884. PubMed ID: 36043457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
    Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
    Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.